Drugs in development · updated 13 November 2026
JS203: clinical trials and development status
As of 13 November 2026 JS203 is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is III.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A recombinant bispecific antibody targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/CD3 bispecific antibody JS203 binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Diffuse large B-cell lymphoma | III | 1 | NCT07808827 |
| B-cell lymphoma | II | 2 | NCT07081022 |
Everything on JS203
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.